Dose-Escalated SBRT for Borderline and Locally Advanced Pancreatic Cancer: Resectability Rate and Pathological Results of a Multicenter Prospective Study
Neoadjuvant ChT-SABRT in LAPC improves resectability rates and induces relevant tumor regression. These promising findings should be validated by larger sample sizes and extended follow-up.
Authors
- Pedro C. Lara (ORCID: https://orcid.org/0000-0003-1709-6232)
- Marta Lloret-Saez-Bravo
- A. Kannemann
- Pérez Rodríguez (ORCID: https://orcid.org/0000-0003-2944-8610)
- Maria Soledad Martínez-Martin
- Rodolfo Chicas-Sett (ORCID: https://orcid.org/0000-0001-8127-2523)
- Anoushka M. Afonso (ORCID: https://orcid.org/0000-0002-0194-8173)
- Laura Ferrera-Alayón (ORCID: https://orcid.org/0000-0001-5242-791X)
- Bárbara Salas-Salas (ORCID: https://orcid.org/0000-0002-4336-4045)
- Gabriel García-Plaza
- Andrés Vera-Rosas
- Elisa Salcedo
- Alberto Espinosa-Lopez
Institutions
- Hospital Universitario Insular de Gran Canaria (ES)
- Universidad Fernando Pessoa Canarias (ES)
- Hospital Universitario de Gran Canaria Doctor Negrín (ES)
- Canary Institute of Cancer Research (ES)
- Hospital Universitario Virgen de la Arrixaca (ES)
Publication Details
- Journal
- Cancers
- Published
- 2025-01-09
- DOI
- https://doi.org/10.3390/cancers17020191
- Citations
- 2
- Primary Topic
- Advanced Radiotherapy Techniques
- Type
- article
- Field-Weighted Citation Impact
- 3.77